The in-vitro activity of EN 272, a quinolone-7-carboxylic acid, in comparison with other quinolones.
The in-vitro activity of EN 272, a quinolone-7-carboxylic acid was determined and compared with that of enoxacin, ofloxacin, norfloxacin, ampicillin, cephalexin and trimethoprim. EN 272 inhibited the majority of the Enterobacteriaceae at concentrations of less than or equal to 1.6 mg/l. EN 272 was four- to 32-fold less active than the other new quinolones, but it inhibited organisms resistant to nalidixic acid, ampicillin and cephalexin. EN 272 had poor activity against Pseudomonas aeruginosa and streptococcal species, but it did inhibit most staphylococci at less than or equal to 6.3 mg/l. EN 272 was less active at pH 5.5 and in urine as are other quinolones.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D015365:Enoxacin; D006801:Humans; D008826:Microbial Sensitivity Tests; D009268:Nalidixic Acid / Q000494:pharmacology; D009287:Naphthyridines / Q000494:pharmacology; D009643:Norfloxacin / Q000494:pharmacology; D015242:Ofloxacin; D010078:Oxazines / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology*; D015363:Quinolones; D013329:Structure-Activity Relationship; D014552:Urinary Tract Infections / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D009287:Naphthyridines; D010078:Oxazines; D011804:Quinolines; D015363:Quinolones; D015365:Enoxacin; D009268:Nalidixic Acid; C046819:EN 272; D015242:Ofloxacin; D009643:Norfloxacin